DOCSLIB.ORG

Original Article Ceramide Synthase 6 Predicts Poor Prognosis and Activates the AKT/Mtor/4EBP1 Pathway in High-Grade Serous Ovarian Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Original Article Ceramide Synthase 6 Predicts Poor Prognosis and Activates the AKT/Mtor/4EBP1 Pathway in High-Grade Serous Ovarian Cancer Am J Transl Res 2020;12(9):5924-5939 www.ajtr.org /ISSN:1943-8141/AJTR0111977 Original Article Ceramide synthase 6 predicts poor prognosis and activates the AKT/mTOR/4EBP1 pathway in high-grade serous ovarian cancer Yinong Shi1*, Chen Zhou2*, Huan Lu1, Xiaoxiao Cui1, Jun Li3, Shuheng Jiang3, Hao Zhang4, Rong Zhang1 1Fengxian District Center Hospital Graduate Student Training Base, Jinzhou Medical University, Shanghai 201499, China; 2Department of Obstetrics and Gynecology, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou 213000, Jiangsu, China; 3State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China; 4Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China. *Equal contributors. Received April 5, 2020; Accepted July 26, 2020; Epub September 15, 2020; Published September 30, 2020 Abstract: Objective: Ovarian cancer is one of the most common gynecological malignancies worldwide, and its mor- tality rate ranks first among gynecologic cancers. Ceramide synthases are closely related to cancer development. In this study, we investigated the role of ceramide synthase 6 (CerS6) in the development of serous ovarian cancer. Methods: Expression of CerS6 in cancerous and healthy ovarian tissue was assessed by database analysis and im- munohistochemistry. The biological role of CerS6 in serous ovarian cancer cells was assessed by CerS6 knockdown followed by cell counting, colony formation, transwell migration, wound healing, and flow cytometry assays and mea- surement of tumor proliferation in nude mice. Signaling pathway components were analyzed by Western blotting. Gene enrichment was analyzed by GSEA and R, and RNA sequencing was used to compare the transcriptomes of serous ovarian cancer cells with and without CerS6 knockdown. Results: High CerS6 expression in ovarian cancer tissues was closely related to poor prognosis. Knockdown of CerS6 inhibited serous ovarian cancer cell proliferation, invasion, and metastasis and promoted their apoptosis. In addition, CerS6 knockdown increased the proportion of serous ovarian cancer cells in G2/M phase. CerS6 regulates cell cycle through the AKT/mTOR/4EBP1 signaling pathway, which affects cell proliferation and metastasis. The GSEA, R, and RNA sequencing analyses showed that knocking down CerS6 significantly affects cell cycle in serous ovarian cancer cells. Conclusions: CerS6 may have an oncogenic role in ovarian cancer and may represent a new prognostic marker and therapeutic target for serous ovarian cancer. Keywords: High-grade serous ovarian cancer, CerS6, cell cycle, AKT/mTOR/4EBP1 signaling pathway Introduction 22,500 ovarian cancer-related deaths occurr- ed in 2015 [4]. A recent study reported that Ovarian cancer is one of the three malignant the 5-year survival rate of patients with stage I gynecological tumors. According to the latest ovarian cancer is 90%, whereas the 5-year global cancer statistics, ovarian cancer has the survival rate of patients with stage III and IV highest mortality rate among gynecological ovarian cancer is less than 10% [3]. Although tumors worldwide [1]. Ovarian cancer cases the pathogenesis of ovarian cancer is com- have increased worldwide in recent years [2] plex and unclear, epidemiological and genetic and currently account for 2.5% of all malignant analyses have linked ovarian cancer occur- tumors in women each year [3]. In the United rence with specific genetic mutations [5]. The States, approximately 22,530 new cases of most common mutations associated with ovar- ovarian cancer and 13,980 ovarian cancer- ian cancer, such as those in BRCA1, BRCA2, related deaths occurred in 2019 [1]. In China, and p53, are related to defective homologous 52,100 new cases of ovarian cancer and recombinant DNA repair [6-9] and are accom- Ceramide synthase 6 in high-grade serous ovarian cancer panied by changes in the PI3K/AKT/mTOR and OV15, IGROV1, and CAOV-3 were obtained from RAS/RAF/MEK signaling pathways [10]. the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and the cell lines One of the six identifying hallmarks of tumor OVCAR3, OVCAR8, and HEK293T were obtain- cells is abnormal metabolism [11]. Tumor tis- ed as gifts from Shanghai Cancer Institute sues meet the biological energy, biosynthesis, (Shanghai, China). All cells were cultured ac- and redox requirements for rapid growth th- cording to American Type Culture Collection rough metabolic reprogramming [12]. Cerami- (ATCC) instructions. An anti-CerS6 antibody de synthases, key enzymes in eukaryotic lipid (ab115539, Abcam, Cambridge, UK) was used metabolism that produce ceramide [13], have for Western blotting and immunohistochemis- recently attracted increasing attention within try. Additional Western blotting antibodies rec- the tumor field. The ceramide synthase family ognizing AKT (#4685), p-AKT (#4060), mTOR includes six genes (CerS1-6) [14] that are (#2972), p-mTOR (#2971), 4EBP1 (#9644), and encoded on different chromosomes and syn- p-4EBP1 (#9451) were obtained from Cell thesize fatty acyl-CoAs of different chain Signaling Technology (Danvers, MA, USA), and a lengths [13]. Among them, CerS6, also known primary anti-GAPDH antibody (M1210-2) was as LASS6, mainly synthesizes C16: 0-cera- obtained from Sigma (St. Louis, MO, USA). mide [15], which promotes cell migration and Secondary antibodies were purchased from metastasis and is an important mediator of Jackson ImmunoResearch (West Grove, PA, apoptosis [16, 17]. Many recent studies have USA). shown that CerS6 is involved in the occurren- ce and progression of a variety of tumors. For Clinical samples and database example, CerS6 is highly expressed in breast cancer [18] and non-small-cell lung cancer [17] Human ovarian cancer tissue and normal ovar- cells. Knockdown of CerS6 in non-small-cell ian tissue used in this study were obtained lung cancer cells attenuates lung metastasis from the Department of Obstetrics and Gy- [17], whereas overexpression of CerS6 in hu- necology, Fengxian District Center Hospital man head and neck squamous cell carcinoma Graduate Student Training Base, Jinzhou xenografts leads to their rapid growth [19]. Medical University and the Department of However, few studies have investigated the Obstetrics and Gynecology, The Affiliated mechanistic role of CerS6 in the development Changzhou No. 2 People’s Hospital of Nanjing of ovarian cancer. Medical University. None of the patients re- ceived radiotherapy, chemotherapy, or other In the early stage of this study, we found that related antitumor therapies before surgery. All CerS6 is highly expressed in serous ovarian human tissues were obtained with informed cancer cells and is associated with poor prog- consent, and the study was approved by the nosis. Immunohistochemistry results con- Research Ethics Committee of Fengxian Dis- firmed that high CerS6 expression is closely trict Center Hospital Graduate Student Training related to high-grade and advanced-stage Base, Jinzhou Medical University. We down- serous ovarian cancer. Therefore, in the later loaded and analyzed ovarian cancer cohort stage of this study, we investigated the effect data from the Cancer Genome Atlas (TCGA, of CerS6 on the biological functions of serous https://cancergenome.nih.gov/) and the Gene ovarian cancer cells in vivo and in vitro and Expression Omnibus (GEO, https://www.ncbi. explored the possible mechanism for its role nlm.nih.gov/geo/). in ovarian cancer. Our results indicate that CerS6 may be a new molecular biomarker for Immunohistochemical staining the prognosis of serous ovarian cancer and may represent a new therapeutic target for the Immunohistochemistry was performed as pre- treatment of this common malignancy. viously described in [20] with an anti-CerS6 antibody (1:200, ab115539, Abcam). The in- Materials and methods tensity of CerS6 staining was scored using the following criteria: 0-5% staining was scored as Cell culture and reagents 0; 6-35% staining as 1; 36-70% staining as 2; and > 70% staining as 3. A total score < 2 was The human epithelial ovarian cancer cell lines considered to represent negative expression, HO8910PM, OVCAR5, OVCAR8, ES-2, SKOV-3, and a score ≥ 2 was considered to represent 5925 Am J Transl Res 2020;12(9):5924-5939 Ceramide synthase 6 in high-grade serous ovarian cancer positive expression. The scoring was perfor- Western blotting med in a blinded manner by two senior pathologists. Cells were lysed and cell proteins extract- ed with protein extraction buffer (Sangon, Cell transfection and RNA interference Shanghai, China). Western blotting analysis was performed as described previously [20]. Cells were plated at 70% confluence and trans- fected with CerS6-specific small interfering Cell proliferation assay (CCK-8 assay) RNA (siRNA) or with nontargeted siRNA (Gene- Pharma, Shanghai, China) using Lipofecta- Cell viability was measured using the Cell mine® RNAiMAX (13778150, Invitrogen, Wal- Counting Kit-8 (CCK-8, Dojindo, Japan) accord- tham, MA, USA) following the manufacturer’s ing to the manufacturer’s instructions. Cells instructions. The CerS6 siRNA sequences with the indicated treatments were grown in were as follows: siRNA1 sense, 5’-GCAGGC- 96-well plates at 4,000 cells per well. CCK-8 UGAGGACCUCUAUTT-3’, anti-sense, 5’-AUAGA- was added to each well and incubated for 1 h GGUCCUCAGCCUGCTT-3’; siRNA2 sense, 5’- at 37°C. Absorbance
Load more

Recommended publications
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened.
    [Show full text]
  • Investigation of Adiposity Phenotypes in AA Associated with GALNT10 & Related Pathway Genes
    Investigation of Adiposity Phenotypes in AA Associated With GALNT10 & Related Pathway Genes By Mary E. Stromberg A Dissertation Submitted to the Graduate Faculty of WAKE FOREST UNIVERSITY GRADUATE SCHOOL OF ARTS AND SCIENCES in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY In Molecular Genetics and Genomics December 2018 Winston-Salem, North Carolina Approved by: Donald W. Bowden, Ph.D., Advisor Maggie C.Y. Ng, Ph.D., Advisor Timothy D. Howard, Ph.D., Chair Swapan Das, Ph.D. John P. Parks, Ph.D. Acknowledgements I would first like to thank my mentors, Dr. Bowden and Dr. Ng, for guiding my learning and growth during my years at Wake Forest University School of Medicine. Thank you Dr. Ng for spending so much time ensuring that I learn every detail of every protocol, and supporting me through personal difficulties over the years. Thank you Dr. Bowden for your guidance in making me a better scientist and person. I would like to thank my committee for their patience and the countless meetings we have had in discussing this project. I would like to say thank you to the members of our lab as well as the Parks lab for their support and friendship as well as their contributions to my project. Special thanks to Dean Godwin for his support and understanding. The umbrella program here at WFU has given me the chance to meet some of the best friends I could have wished for. I would like to also thank those who have taught me along the way and helped me to get to this point of my life, with special thanks to the late Dr.
    [Show full text]
  • Altered Mrna Expression Levels of the Major Components of Sphingolipid Metabolism, Ceramide Synthases and Their Clinical Implication in Colorectal Cancer
    ONCOLOGY REPORTS 40: 3489-3500, 2018 Altered mRNA expression levels of the major components of sphingolipid metabolism, ceramide synthases and their clinical implication in colorectal cancer SUNG WON JANG1*, WOO-JAE PARK2*, HYEONJI MIN3, TAEG KYU KWON3,4, SEONG KYU BAEK5, ILSEON HWANG6, SHIN KIM3,4 and JONG-WOOK PARK3,4 1Department of Emergency Medicine, Dongsan Medical Center, Keimyung University, Daegu 41931; 2Department of Biochemistry, College of Medicine, Gachon University, Incheon 21999; 3Department of Immunology, School of Medicine and 4Institute of Medical Science, Keimyung University, Daegu 42601; 5Department of Surgery, Dongsan Medical Center, Keimyung University, Daegu 41931; 6Department of Pathology, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea Received January 11, 2018; Accepted September 3, 2018 DOI: 10.3892/or.2018.6712 Abstract. Ceramide synthases (CerSs) synthesize various CERS5 mRNA levels in The Cancer Genome Atlas Colon ceramides of different acyl chain lengths and serve important and Rectal Cancer dataset. Notably, CERS2 and CERS4, as roles in the proliferation and death of cancer cells by regu- well as CERS5 and CERS6 levels, were positively correlated lating sphingolipid metabolism-related signaling pathways. with each other in Korean patients with CRC. However, the The present study investigated the mRNA expression levels mRNA expression levels of these four CerS genes were not of various CerS genes using mRNA expression data from six associated with any clinicopathological characteristics in independent colorectal cancer (CRC) cohorts and a Korean Korean patients with CRC. Finally, overexpressing CERS2 or CRC dataset. Expression levels of CERS2, CERS5 and CERS6 inhibited the in vitro viability of various CRC cells.
    [Show full text]
  • Download Article (PDF)
    Article in press - uncorrected proof BioMol Concepts, Vol. 1 (2010), pp. 411–422 • Copyright ᮊ by Walter de Gruyter • Berlin • New York. DOI 10.1515/BMC.2010.028 Review Ceramide synthases in mammalians, worms, and insects: emerging schemes Andre´ Voelzmann and Reinhard Bauer* plasmic reticulum (ER) by condensing activated palmitate LIMES Institute, Program Unit Development and Genetics, (palmitoyl-CoA) with L-serine through the activity of serine Laboratory for Molecular Developmental Biology, palmitoyl transferase (SPT); (3). The formed intermediate University of Bonn, Carl-Troll-Str. 31, D-53115 Bonn, 3-ketosphinganine is then turned to sphinganine by the 3- Germany ketosphinganine reductase (4). CerS now catalyze the CoA- dependent dihydroceramide synthesis. In this step, CoA * Corresponding author activated fatty acids are used for aminoacylation of sphin- e-mail: [email protected] ganine carbon-2 (Figure 1). The generated dihydroceramide is further converted to ceramide by dihydroceramide desa- turase. Initially, the molecular identity of enzymes and bio- Abstract chemical pathways of the de novo biosynthetic pathway have The ceramide synthase (CerS) gene family comprises a been identified and characterized, especially in mammalian group of highly conserved transmembrane proteins, which cells and the budding yeast Saccharomyces cerevisiae (5–7). are found in all studied eukaryotes. The key feature of the Thus, it became evident that these lipids and enzymes were CerS proteins is their role in ceramide synthase activity. conserved across species and phyla. Therefore, their original name ‘longevity assurance gene (Lass) homologs’, after the founding member, the yeast lon- gevity assurance gene lag1, was altered to ‘CerS’. All CerS Identification of ceramide synthases have high sequence similarity in a domain called LAG1 motif and a subset of CerS proteins is predicted to contain a Although CerS activity was detected previously in 1970 (8), Homeobox (Hox) domain.
    [Show full text]
  • Supporting Information
    Supporting Information Jensen et al. 10.1073/pnas.1316700111 SI Materials and Methods Western Blot Analysis. For all Western blot analyses, proteins were Cloning of Bcl2L13 and Mutagenesis of Bcl2L13. Full-length Bcl2-like separated by 4–12% SDS/PAGE (Life Technologies), transferred 13 (Bcl2L13) was cloned into pCDNA3-V5-His (Invitrogen) to Hybond PVDF membranes (Amersham), blocked with 5% using unique EcoRV/XhoI restriction sites and into the CSII- (wt/vol) milk in PBS with 0.1% Tween 20 (PBS/Tween) for 1 h, CMV-MCS-IRES2-Venus lentiviral vector via NheI/AgeI re- washed with PBS/Tween, and incubated with the following an- striction sites. To delete the BHNo domain (amino acids 207–459, tibodies: anti-actin (Santa Cruz), anti-Bax (Millipore), anti- – base pairs 621–1377) of Bcl2L13, mutagenesis PCR was em- Bcl2L13 (Proteintech), anti cleaved caspase-3 (Cell Signaling), – – ployed using primers ATACTGCTGTTTGGAGGGGCTGCT- anti cleaved caspase-7 (Cell Signaling), anti cleaved caspase-9 GCTGTTGCC and AAGACTAAACACACAGTGCCCCAGC- (Cell Signaling), anti-COXIV (Cell Signaling), anti-COX17 (Santa Cruz), anti–Bcl-2 (Millipore), anti–Bcl-x (Cell Signaling), CACCTTG that amplified a mutant Bcl2L13 lacking the BHNo L anti-Bak (Cell Signaling), anti-Hsp70 (BD Pharmingen), anti- domain (ΔBHNo). The mutant PCR product was ligated back LASS2 (CerS2; Abnova), anti-LASS6 (CerS6; Abnova), anti- together and was transformed. FLAG (Sigma), anti-HA (Santa Cruz), and anti-V5 (Invitrogen). Lentiviral Production and Infection. 293FT cells were plated in a The blots were washed with PBS/Tween and subsequently were 10-cm dish at 3 × 106 cells per plate. After 24 h, cells were trans- incubated with goat anti-rabbit IgG or with goat anti-mouse fected with 3 μg of target lentiviral construct, 1.25 μg of pMD2.G antibodies (Santa Cruz) in 5% (wt/vol) milk PBS/Tween.
    [Show full text]
  • Biomolecules
    biomolecules Article Ceramide Synthase 6: Comparative Analysis, Phylogeny and Evolution Roger S. Holmes 1,2,*, Keri A. Barron 2 and Natalia I. Krupenko 2,* 1 Griffith Research Institute for Drug Discovery and School of Environment and Science, Griffith University, Nathan, QLD 4111, Australia 2 Department of Nutrition, UNC-Chapel Hill, UNC Nutrition Research Institute, Kannapolis, NC 28081, USA; [email protected] * Correspondence: r.holmes@griffith.edu.au (R.S.H.); [email protected] (N.I.K.); Tel.: +61-4-1058-3348 (R.S.H.); +1-704-250-5054 (N.I.K.) Received: 30 August 2018; Accepted: 1 October 2018; Published: 8 October 2018 Abstract: Ceramide synthase 6 (CerS6, also known as LASS6) is one of the six members of ceramide synthase gene family in humans. Comparisons of CerS6 amino acid sequences and structures as well as of CerS6 gene structures/locations were conducted using data from several vertebrate genome projects. A specific role for the CerS6 gene and protein has been identified as the endoplasmic reticulum C14- and C16-ceramide synthase. Mammalian CerS6 proteins share 90–100% similarity among different species, but are only 22–63% similar to other CerS family members, suggesting that CerS6 is a distinct gene family. Sequence alignments, predicted transmembrane, lumenal and cytoplasmic segments and N-glycosylation sites were also investigated, resulting in identification of the key conserved residues, including the active site as well as C-terminus acidic and serine residues. Mammalian CerS6 genes contain ten exons, are primarily located on the positive strands and transcribed as two major isoforms. The human CERS6 gene promoter harbors a large CpG island (94 CpGs) and multiple transcription factor binding sites (TFBS), which support precise transcriptional regulation and signaling functions.
    [Show full text]
  • A Rapid Ceramide Synthase Activity Using NBD- Sphinganine and Solid Phase Extraction
    methods A rapid ceramide synthase activity using NBD- sphinganine and solid phase extraction † † 1, Rotem Tidhar , * Kacee Sims , Eden Rosenfeld-Gur , * Walter Shaw , and Anthony H. Futerman * Department of Biological Chemistry,* Weizmann Institute of Science , Rehovot 76100, Israel ; and Avanti Polar Lipids Inc. , † Alabaster, AL 35007-9105 Abstract Ceramides are synthesized by six mammalian ce- For many years, CerS activity was assayed using radioac- ramide synthases (CerSs), each of which uses fatty acyl- tive substrates [either 3 H-Sph ( 7 ) or 14 C-labeled acyl-CoAs CoAs of different chain lengths for N -acylation of the ( 20 )], with separation of the substrate and products per- sphingoid long-chain base. We now describe a rapid and reli- formed by TLC. Recently, a fl uorescent Sph analog has able CerS assay that uses a fl uorescent N-[6-[(7-nitrobenzo- become available, ␻ (7-nitro-2-1,3-benzoxadiazol-4-yl) 2-oxa-1,3-diazol-4-yl) (NBD ) sphinganine substrate followed by separation of the NBD-lipid substrate and products (2 S ,3 R )-2-aminooctadecane-1,3-diol (NBD-Sph), which is using solid phase extraction (SPE) C18 chromatography. a substrate for CerS ( 18, 21 ). Clearly, the use of fl uores- SPE chromatography is a quick and reliable alternative cent substrates is preferable to use of radioactive substrates to TLC, and moreover, there is no degradation of either as it avoids radiation hazards ( 21 ). NBD-sphinganine or NBD-ceramide. We have optimized the We now describe an assay using NBD-Sph, in which the assay for use with minimal amounts of protein in a minimal fl uorescent lipid products are separated by solid phase ex- volume.
    [Show full text]
  • Noncoding Variations in the Gene Encoding Ceramide Synthase 6 Are Associated with Type 2 Diabetes in a Large Indigenous Australian Pedigree
    Twin Research and Human Genetics (2019), 22,79–87 doi:10.1017/thg.2019.13 Article Noncoding Variations in the Gene Encoding Ceramide Synthase 6 are Associated with Type 2 Diabetes in a Large Indigenous Australian Pedigree David A. Good1, David L. Duffy2, Manuela Good1, Cheng Xia Guo1, Frances Busfield1, Anthony Shaw1 and Joanne T. E. Shaw1,2,* 1Diabetes Research Laboratories, School of Clinical Medicine Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia and 2QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia Abstract Type 2 diabetes (T2D) is a chronic disease that disproportionately affects Indigenous Australians. We have previously reported the localization of a novel T2D locus by linkage analysis to chromosome 2q24 in a large admixed Indigenous Australian pedigree (Busfield et al. (2002). American Journal of Human Genetics, 70, 349–357). Here we describe fine mapping of this region in this pedigree, with the identification of SNPs showing strong association with T2D: rs3845724 (diabetes p = 7 × 10−4), rs4668106 (diabetes p = 9 × 10−4) and rs529002 (plasma glucose p = 3 × 10−4). These associations were successfully replicated in an independent collection of Indigenous Australian T2D cases and controls. These SNPs all lie within the gene encoding ceramide synthase 6 (CERS6) and thus may regulate ceramide synthesis. Keywords: chronic disease; diabetes; genetic association; indigenous health (Received 20 January 2019; accepted 11 March 2019) Type 2 diabetes (T2D) is characterized by hyperglycemia due to of T2D and associated metabolic disturbances in Indigenous impaired insulin secretion, insulin resistance in muscle and Australians are of substantial importance for study as they are nonsuppressible hepatic glucose production (DeFronzo, 1988).
    [Show full text]
  • Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards
    Table S1. 103 ferroptosis-related genes retrieved from the GeneCards. Gene Symbol Description Category GPX4 Glutathione Peroxidase 4 Protein Coding AIFM2 Apoptosis Inducing Factor Mitochondria Associated 2 Protein Coding TP53 Tumor Protein P53 Protein Coding ACSL4 Acyl-CoA Synthetase Long Chain Family Member 4 Protein Coding SLC7A11 Solute Carrier Family 7 Member 11 Protein Coding VDAC2 Voltage Dependent Anion Channel 2 Protein Coding VDAC3 Voltage Dependent Anion Channel 3 Protein Coding ATG5 Autophagy Related 5 Protein Coding ATG7 Autophagy Related 7 Protein Coding NCOA4 Nuclear Receptor Coactivator 4 Protein Coding HMOX1 Heme Oxygenase 1 Protein Coding SLC3A2 Solute Carrier Family 3 Member 2 Protein Coding ALOX15 Arachidonate 15-Lipoxygenase Protein Coding BECN1 Beclin 1 Protein Coding PRKAA1 Protein Kinase AMP-Activated Catalytic Subunit Alpha 1 Protein Coding SAT1 Spermidine/Spermine N1-Acetyltransferase 1 Protein Coding NF2 Neurofibromin 2 Protein Coding YAP1 Yes1 Associated Transcriptional Regulator Protein Coding FTH1 Ferritin Heavy Chain 1 Protein Coding TF Transferrin Protein Coding TFRC Transferrin Receptor Protein Coding FTL Ferritin Light Chain Protein Coding CYBB Cytochrome B-245 Beta Chain Protein Coding GSS Glutathione Synthetase Protein Coding CP Ceruloplasmin Protein Coding PRNP Prion Protein Protein Coding SLC11A2 Solute Carrier Family 11 Member 2 Protein Coding SLC40A1 Solute Carrier Family 40 Member 1 Protein Coding STEAP3 STEAP3 Metalloreductase Protein Coding ACSL1 Acyl-CoA Synthetase Long Chain Family Member 1 Protein
    [Show full text]
  • Role of Bcl-Rambo in Apoptosis and Mitophagy
    Cell S f ign l o a a li n n r g u Meng/Liwei Zhang/Hongzhi Wang/Haiming Dai, J o J Journal of Cell Signaling Cell Signal 2018, 3:3 ISSN: 2576-1471 DOI: 10.4172/2576-1471.1000192 Commentary Open Access Role of Bcl-rambo in Apoptosis and Mitophagy Fei Meng1,2,#, Liwei Zhang1,#, Hongzhi Wang1,2 and Haiming Dai1,2* 1Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, 230031, China 2Anhui Province Key Laboratory of Medical Physics and Technology, Center of Medical Physics and Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China #Co-first authors *Corresponding author: Haiming Dai, Center of Medical Physics and Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China, Tel: +86-551-62727063; E-mail: [email protected] Received date: September 13, 2018; Accepted date: September 21, 2018; Published date: October 1, 2018 Copyright: ©2018 Meng F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Short Communication mitochondrial apoptotic pathway were added [10,11]. The pro- apoptotic function of Bcl-rambo is mediated by the BHNo domain and Bcl-rambo, also known as Bcl-2 Like protein 13 (Bcl-2-L13), with TM domain rather than the BH domains. While Bcl-2 family proteins homology to Bcl-2 protein and might contain all of the four conserved generally display anti-apoptotic or pro-apoptotic functions through Bcl-2 homology (BH) domains, BH1, BH2, BH3 and BH4 (Figure 1) forming hetero- or homodimers [12,13], however, Bcl-rambo does not [1,2].
    [Show full text]
  • Ceramide Synthase 6: Comparative Analysis, Phylogeny and Evolution
    biomolecules Article Ceramide Synthase 6: Comparative Analysis, Phylogeny and Evolution Roger S. Holmes 1,2,*, Keri A. Barron 2 and Natalia I. Krupenko 2,* 1 Griffith Research Institute for Drug Discovery and School of Environment and Science, Griffith University, Nathan, QLD 4111, Australia 2 Department of Nutrition, UNC-Chapel Hill, UNC Nutrition Research Institute, Kannapolis, NC 28081, USA; [email protected] * Correspondence: r.holmes@griffith.edu.au (R.S.H.); [email protected] (N.I.K.); Tel.: +61-4-1058-3348 (R.S.H.); +1-704-250-5054 (N.I.K.) Received: 30 August 2018; Accepted: 1 October 2018; Published: 8 October 2018 Abstract: Ceramide synthase 6 (CerS6, also known as LASS6) is one of the six members of ceramide synthase gene family in humans. Comparisons of CerS6 amino acid sequences and structures as well as of CerS6 gene structures/locations were conducted using data from several vertebrate genome projects. A specific role for the CerS6 gene and protein has been identified as the endoplasmic reticulum C14- and C16-ceramide synthase. Mammalian CerS6 proteins share 90–100% similarity among different species, but are only 22–63% similar to other CerS family members, suggesting that CerS6 is a distinct gene family. Sequence alignments, predicted transmembrane, lumenal and cytoplasmic segments and N-glycosylation sites were also investigated, resulting in identification of the key conserved residues, including the active site as well as C-terminus acidic and serine residues. Mammalian CerS6 genes contain ten exons, are primarily located on the positive strands and transcribed as two major isoforms. The human CERS6 gene promoter harbors a large CpG island (94 CpGs) and multiple transcription factor binding sites (TFBS), which support precise transcriptional regulation and signaling functions.
    [Show full text]